



Georges

Management



Abstract

2016 Corporate Social Responsibility (CSR) Performance Report

This report provides a comprehensive overview of our CSR performance in 2016. We are committed to creating long-term value for all stakeholders through responsible business practices.

Our focus areas include environmental protection, employee welfare, community support, and ethical business operations. We have implemented various initiatives to address these areas, such as carbon footprint reduction, employee training, and social contribution programs.

We have also established a robust CSR management system, including the appointment of a CSR committee and the implementation of a CSR policy. This system ensures that CSR is integrated into our core business strategy and operations.

In 2016, we achieved significant milestones in our CSR journey. We successfully reduced our carbon emissions, improved our employee satisfaction, and supported various community projects. These achievements demonstrate our commitment to responsible business practices and our ability to create positive social impact.

We will continue to strive for excellence in CSR, embracing innovation and collaboration to address the challenges of the future. We believe that responsible business practices are essential for sustainable growth and long-term success.



The 2016 CSR Performance Report is available at [www.ourcompany.com/csr](#). We encourage all stakeholders to visit our website for more information on our CSR initiatives and performance.

We are proud to be a socially responsible company and committed to making a positive impact on society. Thank you for your support and partnership.

CONTENTS

04 A R

14 A f



42 H f



90 C f f



112 P f I S I

115 F F

116 T f C N

121 T P E

06 H f 2016

32 E f



56 I f



102 C f



122 G O C f S R
P f (GB36002)

131 G R I G4I I

140 A S f SGS


Highlights of 2016

July

August

September

I J , F P 86% f I A ,F H I I S ,F P
 , G P .G P F P ' H f I S f S .B
 f C C H f f f S \$100 S ,
 FDA f S .T f C B H ff , f T f
 F P f , F P ' H G A C f
 . f .T D
 I S , f



December

Drug R&D
 R&D
 R&D
 R&D

YaoPharma
 Launched Venlafaxine Tablets to US Market

Creating
 Growth
 H. Ma
 C., Ltd.

A f 2016, F H B - I S , P ,
 f F P f f
 HL 07 f , f S
 M C ,T S . f S
 HER2 f T f
 f f P S
 T f III . P S
 I C f
 H .A f P , P
 PA-824, f . f .
 S f


G M G ,F P
 T I G
 ff M G
 Af ,H H
 M G C ,L . f
 10 D .T f f
 f , ff
 f

Rewards and Recognitions



Industry Ranking Categories

- July • **Top 100 Pharmaceutical Industry Enterprises of China**
China National Pharmaceutical Industry Information Center of Ministry of Industry and Information
- September • **Ranked 3rd among the Top 100 Strengths of Pharmaceutical Research and Development in China, ranked 2nd among the Strengths of Biopharmaceutical Research and Development in China**
YAOZH.COM
- November • **Ranked 14th among the Top 100 Companies in China Pharmaceutical Industry**
CFDA South Medicine Economic Research Institute, Medicine Economic News
- November • **Top Ten Pharmaceutical Industry Enterprise Group of China**
China Pharmaceutical Industry Association, China Association of Pharmaceutical Commerce
- November • **Top 100 Future Enterprises in China**
ACCA (The Association of Chartered Certified Accountants)
- November • **Most Innovative Multinational Companies**
Bioclub



Main Credit Categories

Corporate Social Responsibility Categories

- January • **Best Investor Relations Award**
Awarding Institution: China Financial Market Financial Magazine
- June • **The Best Overseas Medical Investment Enterprises**
Awarding Institution: China Chamber of Commerce for Import and Export of Medicines and Health Products
- October • **Top 20 Most Competitive Listed Pharmaceutical Companies in China, Top 10 Listed Pharmaceutical Companies with the Highest Investment Value**
Awarding Institution: China Pharmaceutical Enterprise Management Association
- November • **Best Listed Companies in Pharmaceutical Industry**
Awarding Institution: Value Line, China Economic Net, China reform Daily

- January • **The Best Social Responsibility Brand**
Awarding Institution: Media of the Fifth Charity Festival
- July • **Responsibility Innovation Best Case Award for the Year**
Awarding Institution: Jiefang Daily (Shanghai Observer), Shanghai Daily, etc.
- December • **Corporate Social Responsibility of Listed Companies**
ranked 2nd in CSR Development Index and ranked 1st in Report Appraisal Results
Awarding Institution: SSRB, Shanghai Stock Exchange, Xinhuanet, Shanghai Association of Listed Companies, etc.
- December • **Golden Bee Excellent CSR Report 2016 Leading Enterprise Award**
Awarding Institution: MOC China WTO Tribune



M8س8




F P , C ,
1994 S S E (:
600196-SH) A 1998 M B f S E f
H K L (: 02196-HK) O 2012. F
, F P G
C
f C .T G '
f
R&D, f ,
A f f , ,F
P G
S ,C ,T S F ,
S .T G ' R&D f
, , f
.I
I C ,F P G '
f , f
G f ,F P
f f .C ,F P G
f S ,F P
,C '
F P G
f
f ,F P
f ,
P G f ,F f
f
f , ff ,
.F P
f




岳

为爱飞

向上海市福利






G a s a d S a e g

F P G ' f f
 F , f ' f .S ,
 , f .L , f ff f
 f M&A . f f
 f


S G


S G - A C


 M G - AC


 D f -


S D S

 S G - C F P G ' C '

 M G - l f

 B f ; f
 f F P f F G P G f f





Global Business Resources

L f f ,F P G f - , f
F ,F P G f f f

Corporate Governance

F P G f
 M M C C ,P D C M M D C ,M f S
 M C f P I .T , f f
 F P f ,F P .T , f
 ff f G .
 T C S 'M ,B f
 D C S P C D ,B f S ,I D .T 22 ,R&D C ,EHS
 M D ,C ,B P M D D ,C ,B P Aff D D ,A ,H R S
 D D ,I R D C D D ,I ,B D M S
 D C /I C D ,P C (R) I C D M ,M f M M S
 M .I 2016, C /F H I C ,M D , M D
 D .I 2016, f f C f C M .T ,B ' D ' .T
 O M ff D C M ff D ,F P .A
 ff , ff , C ff f f - f
 I B M D C C ,I C M .C C ,O C E C ,
 C M ,C C C ,C C ,R C C ,B ,P f M C ,
 EHS M f C f S , C .I 2016, ff
 M C I M C , C O

Corporate Governance

I , C f L ,S SSE, A L ,C f C G f L
 C R f CSRC L C R 14 C G C
 L R f S E
 A :T f f
 C - f C , f C ,
 f .T B f D C S f , , f
 C
 A B f D :T C f A , f ,
 f B f D A f

f .

A :T C f f f , ,

f C .

A f :T C f f f

A S f I f M D f I f L C CSRC, G f M

E I f D D f L C SSE, SSE, A f A

R I f D D f C C R A f S

M E S f E A I f C R .M ,M , C S f I

f I I f , f A S f M E A R f I

D ,f , , f .I f S f-A R I C

C , S R R f

Integrating the environment into our business strategy

In 2016, we continued to integrate environmental considerations into our business strategy. We have established a dedicated team to manage our environmental risks and opportunities. This team is responsible for identifying and assessing environmental risks, and for developing and implementing measures to mitigate these risks. We have also established a system of environmental indicators to monitor our performance in this area. These indicators include energy consumption, greenhouse gas emissions, and water usage. We have set targets for these indicators and are working to reduce our environmental footprint. We have also implemented a number of measures to improve our environmental performance, such as energy efficiency programs, water conservation programs, and recycling programs. We are committed to continuous improvement in our environmental performance and to meeting our obligations to the environment and to society.

Assessing the environmental impact of our operations

In 2016, we conducted a comprehensive assessment of the environmental impact of our operations. This assessment was based on a number of factors, including the nature of our activities, the location of our operations, and the environmental conditions in the areas where we operate. We used a variety of methods to assess our environmental impact, including site audits, data analysis, and stakeholder consultations. The results of our assessment show that our operations have a significant impact on the environment, particularly in terms of energy consumption, greenhouse gas emissions, and water usage. We have identified a number of areas where we can improve our environmental performance, and we are working to implement measures to address these areas. We are committed to reducing our environmental impact and to meeting our obligations to the environment and to society.

Designing a safe and healthy workplace

In 2016, we continued to design a safe and healthy workplace for our employees. We have implemented a number of measures to improve workplace safety, such as safety training programs, safety audits, and safety committees. We have also implemented a number of measures to improve workplace health, such as ergonomic assessments, health and safety training programs, and health and safety committees. We have established a system of workplace safety and health indicators to monitor our performance in this area. These indicators include the number of safety incidents, the number of lost workdays, and the number of health complaints. We have set targets for these indicators and are working to reduce the number of safety incidents, lost workdays, and health complaints. We are committed to providing a safe and healthy workplace for our employees and to meeting our obligations to our employees and to society.

The Commitment to a Safe and Healthy Workplace

Our commitment to a safe and healthy workplace is a key part of our business strategy. We are committed to providing a safe and healthy workplace for our employees and to meeting our obligations to our employees and to society.

Ma e a A a s

F P , f f f f

I 2016, F P

C , EHS,)f

M f CSR f F P 2016

(CSR) f

(C f f

f f ff

Ide ca f s. es

S C 30 f f

F a f s. e ba

I e. e a de ca ge

C 200

Asses e a da a f s. es

Sc ee g a d assess e


E f f

Sc ee g f a e a s. es

A a a d c a

C f C f

Res d g a e a s. es




- | | | | |
|---------|----------|--------|--------|
| 1 P | 9 A -C | 17 C f | 25 C f |
| 2 R | 10 I | 18 C f | 26 C |
| 3 O f | 11 Q | 19 G | 27 T |
| 4 Q f | 12 T f f | 20 G | 28 A - |
| 5 S f f | 13 P f f | 21 C | 29 I f |
| 6 R , | 14 I f | 22 R | 30 C f |
| 7 C | 15 H | 23 P f | 31 C |
| 8 C | 16 M f | 24 | 32 D |

State of CSR

F P f f .fff
 F P CSR f G .
 F P .I 2016, F P
 CSR A ,GE L , C P
 I J 2016, 12 I F f C S R , C TOT
 M f C f PRC G B 2030 S R A .F
 P , C S G C f C ,C S R P G ,I (C),D P C
 f f
 f

Partnerships for CSR Goals

O 10 M ,C P E A ,C P I A ,C
 A f M D I ,C P C A A ,C A ,C f
 T C M f P C N -P E M C A B .T f
 CSR P G f P f C B .T f
 f f f CSR
 F P f f CSR P G f P f E O 3 A ,
 P f CSR C f F P .F P
 f f f C ,EHS .F P
 f f CSR f f ff



CSR Management










F P G CSR f , , CSR
 f f G .
CSR P S
 F P G .T f f G f-
 f , f G . f ,F P G
 f f

CSR M

P



State of the world

S	E	F	P	R	f	F	P
	. S . P . O	f	f	. I . T . E . C	f f f ff	f	, -
S							
	. P . P . P	f	f	. P . M . C . E . E . P			f
C							
	. M f . S	f		. E . C . E . T		f	f
M /					f		, C
	. P . P . C	f		. E . E . E . O . S . S f			
E					f		
	. A . J			. E . C . G			
S			f		f		
	. F . L . F	f		. O . C . P . A . P			f
G			f				
	. C . S . C		f	. A . P . A		f	f
C / -							
	. T . C			. O . C		f	
P /							
	. F . S	f		. C . C . P			
P							

State de E gage e

State des (I . es)

If
 T I R C D D f F P
 f ;
 I
 E- f
 E- f f SSE .M , I R

S. 

I 2016, F P P B S f P
T M f S F P (G) C ., L T ff L
P M A I f S F P (G) C ., L
T ff ;
F P -
f f f
A f F P G f f f

Peer  


F P .I 2016, f F P f
I J , F P , CIMC, M G
2016 A M f C E A -F A ,
I S , B f F P C C f
- .I N , f A , f
f
I O , F P 2016 F P B I
C I S T I C f S
C , f F P f F P ;
I D , 9 G B I F f CSR R f C 12
I F f S R C TOT , F P
CSR f

Partners and  

F P - .I 2016,
P f F
F P P f F P S S C
I S , P C
S J C
f P .T P f F P f S
P f P S f P D , P f T
P f T

C .  , -g .e e 'a 'ga 

I 2016, F P G 35 ,
I 2016, f G 100 f ,
T f .T
f 90
f ff ;



C 35



T 90

TeP. b

F P f f f ;

T f F P , ff C f f F P P , ff (

L I), f .

I 2016, F P ff f

;

F P G , ff C

f

F P f f f G , .F

P ' B P R D

f

.I 2016, F P f f

f F P I S ,I . f

G ;

F P I 2016, 250,471

P f I F P .A , f G

Rea s e g . e e

f

F P 2016 P C L f Off D

C 2016 M S C I D C

f C B f 100 ff f , 30 , f C f

C ;

F P Q f D M f C 2016 f 30

ff f f C f 20 ;

F P 20 f ff .I f

f

P

F P f A M R f P A P L ,

f ;

T f C , f M f I f I f 13 F - P ,

f P I f ;

S CPPCC S CPPCC f

;

P f f D P f H I

S ;

T D R D D f CFDA f C T f S C f M S C

P f M D B , f E f C T S C f M D

f ,

A f

T R E f G L B f B - I ,R&D

P H , f C P ' P

S ;

H P f S T P f S C .T

f H P T P f S C .T

f .I C A A - A

N - f F D T A A C A -

f C A A ;

T S f B f f ;

G H P S B f C f

G H , ff f f

F P E H B f C H A
f - f SASAC, f C , -
f f - .

E es

P f E ' f f
T f F P .T f G , f
f F P ; ' f
T C ff ' .T ff f
f ' f
I 2016, f F P 500
; f ff ;
f f ; f ;
f f ; f ;
f f ; f ;
(, f - ; f)



P f F

A .T f f G H f
G 2016;
T N F f C N , f 12 C ' D
2016. f

S F P .I f C ,
f C .F' f C ,
f C ;

F M -I f B f E '
ff f C ; APP f C P QR f
f C () .E QR
f .T

Sf S f f G f f f

Share de C . & Feedback

T f f 2016 CSR f f f 2015.I
2015, G 200 ,
GE, H G CSR B .T C A ,
f f , f , f , f F
P , CSR , .




Ke . a d a l d a f f . P a a G .

--	--	--	--	--	--	--	--

--	--	--	--	--	--	--	--

Re . e . e f . b . s e s s e g e s



I . e s e e e e a c a d d e e e

--	--	--	--	--	--

--	--	--	--	--	--



O e a g Res.

I 2016, F P G ,f ,f ,f ,f



R&D Performance


R&D Investment of Fosun Pharma Group for 2012-2016 (RMB1,000,000)

D
R&D
- R&D f

F R&D f
G + +
+

986
R&D R S

D R&D
C -
R&D



In 2016, R&D investment reached RMB1,106 million (an increase of 33.23% over 2015).

R&DI Investment

Total R&D investment in 2016 was RMB1,106 million, an increase of 33.23% over 2015. R&DI investment in 2016 was RMB963 million, an increase of 6.67% over 2015. R&DI investment as a percentage of total R&D investment was 86.7% in 2016, compared to 86.3% in 2015.

R&D Progress

In 2016, we completed the Phase I clinical trial of HL07, a novel EGFR inhibitor. HL07 is currently in Phase II clinical trial. We also completed the Phase I clinical trial of MPA-824, a novel anti-angiogenic agent. MPA-824 is currently in Phase II clinical trial. We also completed the Phase I clinical trial of SPT, a novel anti-cancer agent. SPT is currently in Phase II clinical trial.

Patent Applications

In 2016, we filed 103 patent applications, an increase of 21.2% over 2015. We received 22 patent grants, an increase of 2.1% over 2015. The number of patent grants as a percentage of patent applications was 21.4% in 2016, compared to 20.4% in 2015.

Patent Applications and Grants

In 2016, we filed 103 patent applications, an increase of 21.2% over 2015. We received 22 patent grants, an increase of 2.1% over 2015. The number of patent grants as a percentage of patent applications was 21.4% in 2016, compared to 20.4% in 2015. The number of patent grants as a percentage of total R&D investment was 1.9% in 2016, compared to 1.8% in 2015.

T A M P

T	A	M	P						
	P	INN		I					
	A	R P	G	F	f		B		
	S L	P I	I	F	f	ll			
M	S P	G	T	F	f	ll			
	B	R E	H f I	F -			ff		
	L T	F		F	-	f		f	
	N/A	C		F	f	- f , ,			
	A	M C	A I	T			, f ,		
	D E	A f I	D E	T					
	K	D		T					
C	B T	H I	- f	T					
	B T	T		F	f				
	B	P		H	f				
	M	C	f	F	,	,	,	,	,
B	A D J	D I	C f B	T	(f) f		
	Q	Q T	F	T			f		
A - f	ARTES NPL S	A	P	M			, M	f	
	ARTES N								
	C f C	C f f	S	T	f		f		
	S D L K		f	I	f	f		f	
	N N K	E P I	H R f T	F	-	-			
A - f	N/A	Rf		I	f		f		
	Q S S L	G S L	P S S	F	f				
	E B	S I	.56-0.349-000	(7 T L 005	0)1-10.016E	11 (()	0 13.228 0.421P	(11)	1T 00(D 7 T f)13.

Healthcare Services

I 2016, RMB1,677.56, f 21.67% 2015. G f
 I 2016, G f f -
 - - ,f , -ff ,
 f f
 I 2016, P II f Q Q H f S f G
 f H G H f G
 G , I) f , f H C H ,
 B H) , f f C f
 f , f .T G C M
 G , f f G f - f -
 f f .S f
 .F f , G f
 L .T f f B f f M J Q C
 f f ff f f O20
 A H , G H H) (C H ,J
 C H ,G H H) G , 3,018.
 F , G F H C (CHD).
 I 2016, F H f B ,S T
 F H H Q S P F H f f G
 f , G f

Medical Devices and Medical diagnostics

I 2016, G .T f f
 RMB2,663.91 , 18.17% 2015.
 I 2016, A L C I .I 2016, A L f ,
 f RMB786.21 , 14.19% 2015. I f ,
 R&D f
 .I 2016, f A L f 6 E CE f
 .S.FDA f . f S G
 f A L , 2016, G f f S G
 S E .
 I 2016, G .D ff CML - f
 , f , f f ,
 f f f
 2016, f f f D f .I
 2016, M C H K , 54% 2015. 19,000
 M , C I S ,
 f f D ,
 f f ,
 I S , f I S f f

Partnerships and Research

In 2016, S... f... G... f... .I...
 2016, S... f RMB258,388... f f RMB6,892...
 f RMB4,647... 12.99%, 20.04% 23.20%, f 2015.
 A... f 2016, C...T... f S... 31... ,
 f... 1,991 f... -... 14,231 (...
 -...).D... R... P... ,S... '... f...
 13.34%
 f 2015 RMB246,459... .M... f S...
 f RMB10,239... R... P... ,
 f 17.29%... f 2015,
 f... G... D... D...
 S... ,... ,... 3,502.

Creation of value through M&A and Rega

In 2016, G... f... , G... ,f...
 f... G...



A
(C
f F P G 2012-2016
f f)
(RMB10,000)

L	f F	P	G					(RMB10,000)
	'	'	S	H	T	E	O	* T
				f	f	f f		
2016	180,612	26,615	7,673	2,001	7,614	841	225,356	
2015	164,832	22,936	6,345	1,519	4,962	3	200,597	
2014	131,210	20,678	4,759	1,408	4,850	285	163,190	
*N :O	f	-	f	.				

We . Ge a H s Ba

J 2016, G H .T
f f C ,
f C ff .T
f C - -
f C F

Y. G a g a Med ta I . es e e Ma age e C a L B ed

C G L M I M
f P ' N .1 P H C I F P N .1
T
f f ,
.A f ' C H f
B H ,
f



爱满新世界 暨爱乐之夜

O 9 S , S O C F , F
f F C N : L L F N A
f S f C C R C
ff f , . f
f f f . ff f f f
M , S C - F f ,
l f . A f - , f f l'
. T f .
M . L ,






P f ,



E a ce . a a a age e



I 2016, f O P Q A
f l C f F P 13 f
f 14 .

I e e a s e C s . c

F P G

I	2015	2016
D S A /	77	58
N f f	358	401

f
f ff ,

I e e Q a s e C e ca

13
ce b
cGMC

C , G 13 API f GMCf FDA f
SA, E , M f H f J , H B f G .
.G P 1
f API (5 API), f
2
HO-PQ f P 1 f
f H f C
FDA f SA.



Pa a e a a g

I 2016, F P G
f

f ,
.

I e c s e s e e

I e ea e e e e a s a

P f

I 2016, C H
E H f I M
S (NHFPC H N)

S. f . a B . d. c S a d

S. e. B. ces


P f F P f , .S A 2016, F P ff f f R
 A T f f G , EHS
 F P f f
 M ff f
 R f F P G
 f C C .T C
 f C .T C
 f f f f f f
 C f f f f f f
 F P G f f f f
 f R&D, f f
 .M f f f
 f - ,R&D, f f f
 H f f f G .M
 f f f P G - f f .I 2016,
 f 3,018

C . c f . a B . s . e . s

I 2015, f f P
 G f P D M Q M F M E L Q
 C P f P M L
 I 2016, G f f GMP
 .B f f G GMP f
 f GMP GMP
 .T 2016 f
 I 2016, O M D f G f f P Q
 f I .I f F P 13 f O P Q
 A f I C f F P 13 f O P Q
 .I 2016, 14
 P .T B E f G P
 f f f f f f
 .T O M D f f - - f CAPA
 F f f GMP, G f f
 GMP, G f f
 G , f , OOS - f f
 f , F P f
 I 2016, G f f 58
 .A f f 2010 GMP GMP .T f
 401 .I 2016, f f f
 M f F P G f f f
 T f ff f
 M I S M R



M
3,018



I 2016, f O f
 P Q A f
 I C f F f
 P 13 f .14

100%

401 f ff 58
 f ff

.T
.E f f f f ff f
f f f ff f
I 2016, ISO13485
CE f f
.A
f F P f f f ff f
f f f- .A f

I	S	P	S	f F	P	G	D	F	A
	S		I	D	F	S	A	D	R f
	H P			0			16		P
	A P			2			14		P
	A			3			0		P
	F			7			5		P
	H P			5			33		P
	B			1			22		P
	T			2			15		P
	P			0			39		P
	C B			5			1		P
	J			4			0		P
	S			3			1		P
	S S			1			0		P
	D P			2			13		P
	E P			2			60		P
	G P			9			39		P
	P			5			136		P
	C f P			2			7		P
	H P			0			0		P
	R P			4			0		P
	S H			2			0		P
	T			58			401		P

S	C	R	I	f M	D	S	f F	P	G
S		D		A			S	f A	R
P	E	F	2016	.S.FDA	C (II), (III), (I), O		(I), (III), (I), (I),		EIR
P		A	2016	.S.FDA	f)		(f		O EIR
C	R	M	2016	.S.FDA	I T R , N ' D) , A (F P f				
G	P	M	2016		A , f ,				P -
G	P	M	2016	HO	P f f (OSD-I)				
H	M	12 16J	2016	D N (DN)	ISO13485 C , CE C C II , CE C C III		(INJ-I INJ-II)		P f
S	T	f	24 26 A	2016	T R	EN ISO9001, EN ISO13485, CE C	f P		Q
L	T	f	30 31 M	2016	T R LGA P G H	EN ISO 13485, EN I13485:2012/AC			Q


N : E A

Marketing & Sales

I 2016, f F P G
 S f F P G 2016.T P f 6,550 .Q
 D f 2016, f F P G .l , ff f
 f f .R f f f
 M , f F P G 2016.A f f
 f .A f
 M f - f G f f - f .T
 f f .T f f
 M f f F P G ff f .A
 f .A f f .A
 D 300 f 2016, f F P G 2016.Q
 M C f G 2016 40,000 f 24- f 5,100 ,
 2,000



C
>40,000
 H
>5,100
 O -
>2,000



Q. a Safe T. a g

I f ,f
G ' .K
f f f f
f , f
ff f
GMP f
I 2016, G f f .A
23 f
I f R f S A f
M D , f F
P G ff f

S. Manage e

S .T f f f f f

f f .

I 2016, f f 8 ,F

P f f B G ,F

f G S M f F P G H S (T),

M ITP M M f F P G (T),M N -

P P M f F P G (T),M f M

f C P P f S F P (G)C „L (R),T

f T D P f P f P S f F „P ,T f

D f P T S P f F P ,T f D f

P P T f M S T f T D f l f

P f F P f , f - f

G .

S 2016

f .C , G f f ,

, , , .T f ,

ff .M , f F P ,

f .T G -

f f f

.I 2016,F P f , f ,447 557 110

f .T

.I 2016,F P f ,

,F P f

f f

I 2016,F P f f 2015 f f

f (f / f), f 671 .T

f f F P

f f

A f F P f f (

- , ff f) f

, f f

I f , , G

f , f f f , f

f , f , f f ,

P f f f f f

f f f f f .T f

f f .D f f

ff .T G f f

f f .S f f f

F P f f f

M .F f f

T f f f f f .T f F P

f 14 .M f F P


I 2016, f F ' P

557

447

110_f


F P f f
671




S M f M P S f F P G 2016

S G P B A P E P P

N f







O C ' D , f F P



Implementation of EHS Program

Management of EHS System

Fosun Pharma Group (Fosun Pharma) has established a comprehensive EHS management system, including the EHS Handbook, EHS training, EHS audit, and EHS reporting-out, to ensure the effective implementation of EHS management.



Management

At the Moment of the Brand section of the 2016 Fosun Pharma annual meeting, the senior management members of Fosun Pharma (including the Chairman and President) signed the commitment for quality and EHS, and released the commitment to the stakeholders of Fosun Pharma that Fosun Pharma will create better and happier life for the people through innovation.



Measurement System operation & Monitoring

To continue implement the guidelines and basic requirements described in Fosun Pharma The Environment, Health and Safety (EHS) handbook, including EHS seminars, EHS technical & awareness trainings, risk identification and assessment, cross audit, routine & non-routine inspection, EHS concern reported-out, and EHS red/yellow flagged issues. It's the first time to highlight and enhance the reporting-out requirement for EHS accident/incident/potential risks. The relating management team may finally be held accountable for their any violation to the incident report procedure, which aims to enhance the EHS management and control level and to minimize the EHS risks by strengthening the EHS management in a top-down approach.



Group Internal Audit

The EHS audit scope within the subsidiary, with the more subsidiaries, two more Business Units being involved in Y2016. Two major business units (medical diagnosis and medical devices) of Fosun Pharma Group for the first time, which marked the extended application of EHS management system on Fosun Pharma Group's subsidiaries in medium and smaller segments, and paved the way for intensive implementation of EHS system in Fosun Pharma Group.



External Certification

The subsidiaries voluntarily took further steps to carry out external third party certification/assessment. By the end of Y2016, totally 10 subsidiaries of the Group received third party certifications of ISO 14001 and/or OSHAS 18001, and 21 subsidiaries passed the third party assessment on safety standardization of the PRC, representing an increase of 1 and 8 subsidiaries, respectively, as compared with last year.

EHS		2016	
Subsidiary	Certification	Subsidiary	Certification
B	ISO14001, OHSAS18001, C III S f S	E P	ISO14001, OHSAS18001, C III S f S
J	ISO14001, OHSAS18001, C III S f S	C f P	ISO14001, OHSAS18001, C II S f S
P	ISO14001, OHSAS18001, C II S f S	P	ISO14001, OHSAS18001, C II S f S
S S	ISO14001, OHSAS18001, C III S f S	H P	ISO14001, OHSAS18001, C II S f S
F	ISO14001, OHSAS18001, C III S f S	J C H	ISO14001, C III S f S
C B	T II S f S	R P	T III S f S
D P	T III S f S	G H	T III S f S
A	T III S f S	L M M	T II S f S
G P	T III S f S	F B	T II S f S
H P	T II S f S	H. a. Med. a.	T III Safe S. a. d. a. a.
S T f	T III S f S		

Case: Teaching of BBS WeChat application

Fosun Pharma Group has established a comprehensive EHS management system, including the EHS Handbook, EHS training, EHS audit, and EHS reporting-out, to ensure the effective implementation of EHS management.



Figure 1: EHS隐患排查改进系统

EHS Policy, Health and Safety (EHS) Policy

EHS



F P
f
f
F P EHS
T F P
EHS

1. C (EHS) C / E ; H Sf
EHS

2. I f f
f

3. P ff f f f

4. C f - f f

5. C f EHS f .M f EHS
EHS
EHS EHS

6. C EHS f EHS
EHS EHS

F P , f f EHS .T
f
EHS

E g C S. 

1) :T
 8,769,376 , f 52,439 0.6% f 2015. f
 , 1.61% , 2016 139,000
 RMB10,000, - - 2015. T 5.99 /
 D 2016, S S f 1.9 24.1% .
 396,000 f ff f ,

2)E :T 478,175,186 ,
 53,707,564 12.7% 2015. I 2016,
 D P , F L T f f
 ()- .D f f
 S S , f G f 2016.

3)O :O
 185,690,272 f , 12,276,649 f 7.1%
 f 2015. O 126.93 f /


139 (13 2.625 TD) -4.5 () 5 92)5.7 0 ()-8 (. () ()5.7))38 () O J0.011 T 1 (T 26 (.))38 () O -4.5 ()5

C	f E /	C	F P G	T f	O	E f	RMB10,000 f	RMB10,000
T	f	T	f E	(/)	(/)	(/)	(/)	(/RMB10,000)
2012	6,175,823	249,387,502		79,928,627				
2013	7,777,884	365,006,317	44,859,276	120,177,461	165,036,737			
2014	8,377,364	421,765,752	51,835,011	122,713,255	174,548,266	171.56	8.23	
2015	8,716,937	424,467,622	52,209,518	121,204,106	173,413,623	157.01	7.89	
2016	8,769,376	478,175,186	58,815,548	126,874,724	185,690,272	126.93	5.99	


B	f	E	C	f	M	S	f	F	P	G	2016
N	f	E	N	L	C	S	R	C	D	G	F
		()	(³)	()	(³)	()	()	()	(L)	(L)	()
	B	9,100,000		15,600		27,112,000			200	74,300	
	J	8,030,000		8,400		28,458,000					
	P	6,385,400	5,338			11,997,000				15,080	
C	B	7,021,980				12,629,320			5,301	12,569	
	F	1,353,675	353,787	2,313					180	35,700	
	S	333,900		1,800		955,000				16,500	
D	P	9,358,414	1,283,596					8,855,000	350	6,898	
	A	5,118,909		2,890		13,867,860				18,991	
	G	30,072,609	805,820					7,649,000	1,078	12,614	
	S	292,250,000						122,400,000			
H	P	2,634,503		2,400		4,983,300			400	18,650	
A	P	7,078,740		10,617	5,009,029				139,324	51,484	
H	P	1,021,655		5,550					21,849	28,081	371,530
E	P	16,096,174		831		34,829,000			4,008	29,705	
C	f	6,018,550	41,846			11,135,340					
	P	29,640,192	2,835,488						5,780	28,233	
	T	29,119				2,979,000				9,600	
	T	513,300	109,820						76,393	31,649	
S	H	2,885,625							750,000	5,636	
S	T	5,768,580								4,651	
C	R	1,247,716	36,020							15,730	
	R	2,416,970				4,920,300			400	100	
	F	220,420									
	G	2,789,010	156,250						6,569	9,600	
	H	4,555,651								8,289	14,569
C	H	11,930,000	854,000						14,924	31,164	
J	C	1,666,000	48,985						5,900	22,000	
	G	1,942,106							10	1,800	
C	M	246,443								500	
	B	804,042								6,531	
L	M	1,858,608							100	20,000	
	F	309,768							100		
		158,182									
F	M	157,114							360	4,200	
	H	1,218,783							12,820	19,970	
C	(B)	47,717									
C	S	20,151							5,000		
S	T	2,884,972							316,000	5,800	
L	T	2,060,000	237,911								
	A	925,208									
C	T	5,000									

Water usage

In 2016, the Group's total water consumption was 8,769,376 cubic meters, representing a 6.42% increase compared to 8,238,081 cubic meters in 2015. This increase is primarily due to the expansion of production capacity in the Asia-Pacific region, particularly in China and India, where water-intensive manufacturing processes are prevalent. The Group continues to invest in water-saving technologies and infrastructure to optimize resource usage across all operations.



Water usage by region



Region	2016 (cubic meters)	2015 (cubic meters)	% Change
North America	1,300	1,300	0%
Europe	31,800	31,800	0%
Asia-Pacific	8,436,276	7,875,281	6.42%
Latin America	7,415	7,415	0%
Africa	30	30	0%
Total	8,769,376	8,238,081	6.42%

T		f		f F		P		G		2016		
N	f	T	f	N	f	T	f	A	R	R		
S	1.R	C	()			8,000		6,000	-	-		
	2.A	C				1,030		859	-	-		
		S					1,030		859	-	-	
		E	()				25.4		25.4	25.4	100%	
	3.P	A	()				416		247	-	-	
		M	(LDPE)	()			2,000		660	-	-	
		C					0		247	247	100%	
		H	()	()			1,000		500	-	-	
	D P	1.R	M				98,500		86,600	-	-	
			L				70,000		62,000	-	-	
L						42,720		42,720	-	-		
2.A		T					67,520		67,520	45,000	66.6%	
		D					2,000		1,529	-	-	
		L					20,300		17,490	-	-	
		C					16,375		11,687	-	-	
		M					2,030		1,450.5	-	-	
		S					3,503		3,703	-	-	
		3.P	P	(0,000)				1.43		1.42	0.14	9.6%
P	(0,000)					18.46		15.87	0.3	1.9%		
A	1.R											

T , f f F P G 2016

N	f	T	f	N	f	T	f	A	R	R	
		1.R	P	(0,000)				474.94	474.75	-	-
				S ()				1,749	1,657	-	-
T		2.A		A ()				38	41	-	-
				R (L)				3,000	850	-	-
				P ()				22	22.9	-	-
				A ()				11.8	10.15	10.15	100%
		1.R	G	,	-	,	-	N	N		
S		2.A		A	f			N	N		
H		3.P		R	,			N	N		
		1.R		B				15	15	-	-
				T				15	15	-	-
				C	M			165	165	-	-
		2.A		S				50-		N	9822 38 I-1.474 -L)
S	T										
P											

Waste and effluent

T f COD 490 2016,
 f 0.5% 2015.T f NH₃-N 60.55 ,
 f 8.1% 2015.F P G



D , f , f .
 G .

D	f	f	f F P G	2016						
N	f	T f D	CODf	NH ₃ -N	f	f	f		D	
		()	()	f ()	(/)	(/)	(/)			
B		163,450	23.864	0.670					P	
J		91,000	9.282	0.002					P	
P		18,584	0.855	0.003					P	
C B		53,919	1.941	0.511					T	P
F		7,200	0.504	0.017					P	
S		21,000	0.000	0.000	N				H	T P
D P		313,286.4	18.703	2.115					D	D C P
A		52,180	3.340	0.000					P	
G P		576,562	40.359	0.000					P	
S S		3,722,626	279.197	44.672					D	f R
H P		36,586	1.463	0.013					P	
A P		80,000	9.600	0.000					P	
H P		36,188	0.984	0.090					P	
E P		197,104	16.872	0.487					P	
C f P		80,937	3.262	1.531					S F	D p C L
P		96,417	3.754	0.329					P	
T		12,952.26	2.590	0.000					Q	T C
T		93,349.65	0.000	0.000					P	S T P
S H		6,083	0.274	0.091					T	C
S T P		972	0.292	0.010					P	
C R		33,909.6	3.221	0.458					P	
I										
R P		12,150	3.038	0.122					P	
F P		2,285.6	0.217	0.031					P	
G H		221,800	12.643	0.956	N				D	L
H		118,926.9	3.496	0.035					C	
C H		332,279	8.307	5.316					C	
J C H		148,252.8	12.572	1.097					P	
H G		136,194	9.806	1.634					P	
C M		656	0.033	0.005	N				P	
B		6,531	0.000	0.000	N				P	
L M M		5,052	0.808	0.019					P	
F B		842	0.135	0.003					P	
		1,043.57	0.000	0.000	N				P	
F M S		505	0.000	0.000	N				P	
H M		27,600	2.208	0.276					D	
C (B)		335	0.000	0.000	N				D	
C S		180	0.000	0.000	N				D	
S T f		33,196.5	16.233	0.050	N				P	
L T f		40,000	0.000	0.000					P	
C T		4	0.000	0.000	N/A	N/A	N/A			

Case: Waste Water Treatment & Sewerage collected

I RMB5.11 , J 600 ³/ f f f
 I, II, f .P
 f + f + F - + TRIC + A/O
 f + f .

Case: U grade f Waste Water Treatment & Sewerage

L f f ff , f
 f .T f ,E P ff f COD, BOD SS ff
 f , f .



Ab e >>

A E	f	f F	P	G	2016			
N f	N	S f	P	N -		T	f	
	(/)	(/)	(/)	(/)				
J	0.000	0.001	0.000	0.12	A		;B	F
P	0.000	0.010	0.130	0.07			,	
F	3.359	0.611	0.370	0.00			F	
D P	0.002	0.001	0.000	0.00	D		f	-
G P	32.863	23.886	8.817	0.00	D -		f	
S S	419.839	441.936	6.187	0.00	D f		f	+
A P	0.000	15.747	1.030	0.00			N/A	
H P	3.384	2.269	1.086	0.00			E f	
E P	0.869	0.000	0.185	0.00	E f		35-	
C f P	0.000	0.000	0.000	1.34	M -		,	+ f 20
P	4.007	0.180	0.604	0.00	D			
S T P	0.000	0.000	0.000	0.01	D		f	f
C R I	0.03	0.038	0.013	-			D f f	
R P	0.000	0.000	0.000	0.55	O		f + f -	+
C H	1.414	0.000	0.007	0.00	1.l		f f f	
L M M	0.002	0.000	0.000	0.00	E		f	
S T f	0.010	0.014	0.014	0.00			N/A	
N :T	f							

Case: Beijing Power Generation - Gas Emission Control

The company has implemented various measures to reduce gas emissions, including the use of cleaner fuels and advanced emission control technologies. In 2016, the company's gas emissions were significantly reduced compared to the previous year, demonstrating its commitment to environmental protection and sustainable development.

Case: Transformation of Energy Structure and Emission Reduction

The company has successfully transformed its energy structure, increasing the proportion of clean energy and reducing the overall carbon footprint. This transformation has led to a significant reduction in greenhouse gas emissions, contributing to the company's goal of achieving carbon neutrality by 2030.

S 11 as amended

I 2016, f F P G 80,848.14 .D P ,
F L T f f 3,158
() , 909 f .

I 2016, f G
.E
f , f
f , , .

D f f f F P G 2016										
N f T () H () I (- H () R / I L O () D f f										
H	229.67	146	0	83.67	0	83.67	0	0	H	f
C H	738	535	0	203	0	203	0	0	H	f
J C H	23.87	11.91	11.91	0.04	0	0.04	0	0	H	f
H ^G	192	75	0	117	0	0	0	117	H	f
C M	0.67	0.63	0.02	0.02	0	0	0	0.02	H E S l	f f ,
B	15.3	9.6	0	5.7	0	2.5	0	3.3	H E S l	f f ,
L M M	25.3	12	12	1.3	0	1.3	0	0	H E S l	f f ,
F B	3.37	2.08	1.08	0.21	0	0.21	0	0	H E S l	f f ,
	0.84	0.75	0	0.09	0	0.09	0	0	H E S l	f f ,
F M S	1.51	1.5	0.01	0	0	0	0	0	C E S l	
H M	63	60	3	0	0	0	0	0	S f , E S l	
C (B)	13	13	0	0	0	0	0	0	C E S l	
C S	0.5	0.5	0	0	0	0	0	0	C E S l	
S T f	15	5	10	0	0	0	0	0	C ; ;	f
L T f	78	50	28	0	0	0	0	0	C E S l	
C T	0.08	0.08	0	0	0	0	0	0	C E S l	

I f f F P G 2016										
N f E f E f										
P A (RMB10,000) P A (RMB10,000)										
B O	f , f f ,	9.30	D f , , f ,	35.20						
J T	f f , , ,	519.20	O f , , f , , f	28.50						
P C f	f , ,	45.00	O f f , f ,	42.00						
C B	T f f f	0.35	M f ; ; ; f ;	29.36						
F E	f , f , f / f	22.90	O , , , f ,	17.75						
S A f	, ,	5.00	T f	1.00						
D P	T f f H , f , PS ,	20.00	E , , f , f ,	100.00						
A E		1.00	, , , ,	13.49						
G P	T f f	206.00	, , , f ,	156.00						
S S R	f f , ,	218.00	E , ,	83.00						
H P	E f	1.21	S , , , ,	7.14						


Environmental

2016,
G

FFP G

RMB33.46, RMB20.27
RMB13.19

Environmental
facilities



Environmental 2016

Item	2016	2016
	(RMB10,000)	(RMB10,000)
AP		22.00
HP		14.00
EP	35.10	168.10
PP	10.40	19.50
CFP	136.59	192.90
T	5.31	1.11
T	6.12	
SH		27.00
STP	0.75	5.20
RI	2.00	9.84
RP	622.00	145.00
SF		3.50
GH	12.00	40.00
H		1.48
CH	116.00	103.80
JCH	6.00	0.60
GH		37.29
CM	0.50	0.88
LM		7.00
FB		0.80
FS		6.00
HM	2.40	1.50
C(B)	4.39	0.45
ST	3.00	3.00
LT		8.05
CT		3.00

Green Star

Carab

I 2016, F P

G F F P G
C f C , ,

ff

f




I 2016, F P G
 f f
 f f
 .A
 S
 A f f 2016,9 f F P G
 f
 F 2016, F P G EHS
 (f),
 f f
 .f .T
 ,F P G
 f f



Occ. a a ea a d safe


F P G
 .I 2016, F P
 f f f
 I 2016 ,F P 0 ,703 f f ,
 f f



Safe

F P f
 () .T EHS
 GB6441-86 <T S C I A F I
 f E E > OSHA .L
 ()
 I 2016, f 20 0.044 (8)f ,0.072 (13)
 f ,0.116 (21)f (), 0.21 (38)
 f .C f 2015, f 69.6%,
 f 81.7%, f 72.7%,
 f 60.7%. A ff
 F P f f ,
 f
 F P f (PSM) API f
 .A .B ff , 2016,0f

A f 2016



A f - 2016



F P ff f , - , - ,EHS

S f I f f F P G 2016

N f	T f T	()	M S	I f C				I f	IH	D f LTC					
				N f	N f	N f	N f								
B	779	1,607,070	0	0	1	0	1	0.12	0.00	1	3	0.12	0.37	0	105
J	169	344,110	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
P	306	708,990	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
C B	157	375,303	0	0	0	1	1	0.53	0.00	1	2	0.53	1.07	0	40
F	210	443,520	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
S	98	250,880	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
D P	943	1,968,984	0	0	1	1	2	0.20	0.00	2	3	0.20	0.30	0	212
A	301	660,030	0	0	0	0	0	0.00	0.00	0	1	0.00	0.30	0	0
G P	1,155	2,310,000	0	0	0	2	2	0.17	0.00	2	3	0.17	0.26	0	84
S S	1,860	4,464,000	0	0	3	0	3	0.13	0.00	3	3	0.13	0.13	0	350
H P	289	622,104	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
A P	613	1,331,090	0	0	0	0	0	0.00	0.00	0	1	0.00	0.15	0	0
H P	369	734,768	0	0	0	0	0	0.00	0.00	0	5	0.00	1.36	0	0
E P	789	1,841,777	0	0	0	2	2	0.22	0.00	2	2	0.22	0.22	0	65
C f P	316	740,918	0	0	1	2	3	0.81	0.00	3	5	0.81	1.35	0	160
P	1,195	2,495,160	0	0	0	1	1	0.08	0.00	1	2	0.08	0.16	0	25
T	88	198,904	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
T	28	6,368	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
S H	292	511,704	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
S T P	95	198,360	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
C I R	248	496,000	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
R P	148	340,000	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
S F	31	80,600	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
G H	541	1,137,552	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
H	660	1,326,480	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
C H	1,700	4,406,400	0	0	1	3	4	0.18	0.00	4	6	0.18	0.27	0	270
J C H	307	677,856	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
G H	291	584,328	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
C M	19	30,818	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
F M -T	151	280,000	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
L M M	321	656,588	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
F B	18	36,860	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
	67	102,137	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
F D	89	154,784	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
H M	577	1,505,970	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
C (B)	51	96,024	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
C S	126	245,844	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
S T f	231	616,875	0	0	1	0	1	0.32	0.00	1	1	0.32	0.32	0	110
L T f	186	428,544	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0
A	213	444,744	0	0	0	0	0	0.00	0.00	0	1	0.00	0.45	0	0
C T	4	3,392	0	0	0	0	0	0.00	0.00	0	0	0.00	0.00	0	0

Note: 1. 1 minor injury incident in the headquarter of the Fosun Pharma Group was included in the lost-time cases and recordable injury cases;

2. (Total, Lost-time, Recordable) Rate = (Total, Lost-time, Recordable) Number * 200,000 / Total Working Hours

Case: 1 ... **cess safe** ... **R. eP a**


R P RMB6.05 DCS, f
 API .F .I R ,DCS .I API ,
 f f .

Case: Mec a ... **ec** ... **Sec. e .**

I F D C S , .I 2016, F D C S .T
 .T f (.A ,) f

Occ. a a Hea


F P f
 D F P (),
 .I 2016, 2,417 (, 100%)
 0.T f 100%.



I		f f		f F P G		I		f f		
N f		P		A (RMB10,000)		P		A (RMB10,000)		
F S M	I f	(,)	9.50	P	f f	,	f	3.80
H M	E f	,	,)	1.10					2.70
C (B)	P	f	f	f	13.00	Sf	,	f	f	5.00
S T f	P	f	f	f	0.70	I	f			1.00
L T f	F									

E ee E gage e

F P f		EHS		C F L	
f		EHS		EHS	
I 2016, F	P	ff	EHS	f	.T
5.75	93,431	34,913	-	2.15	22.2%
	2015.				



S	M				M
B	EHS	B	R	EHS	f
J	EHS	F		f	A C R EHS
F	EHS	T	7		LOTO
		f	C	EHS	f EHS
S	EHS	T	A	f	EHS ; B f
D	P	EHS	T C J ;	C O H I (- f) A ;E	GMP f A EHS ;2015 f f f
A	Sf	Sf		f f	
G	P	EHS	C	f	Sf f f
H	P	EHS	I	f	EHS
A	P	Sf	Sf	f	A C MSDS f f f
H	P	EHS	R	EHS	f f EHS f (EHS)
E	P	EHS	H	EHS	EHS
EHS	P	EHS	1. EHS	EHS	;
B	f f	f f	2. EHS	f	;
			3. EHS	f	;
			4.C		;
			5.I		;
T	Sf	C			
T	EHS	T	f	H	
S	H	EHS	f	H	f f
S	T	P	EHS	F	f f
R	C	I	EHS	A	EHS EHS
R	P	Sf	H	4 f	3 2 2 11
S	F	L	C	f	f f
H	EHS	T			EHS T 5 EHS
L	M	EHS	Sf		EHS
F	B	EHS	Sf		EHS
H	M	EHS	T	f	11 N 2016
S	T	f	Sf	R	EHS f EHS
L	T	f	EHS	F	f A C EHS

Disclosure description: 1. The report discloses the health, safety and environmental protection quality, which is part of the working environment quality and has important effect on the Group. They include the related important performance indicators. For some key indicators which have general effect on the Group, the report has also made voluntary disclosure to some extent. 2. Six new subsidiaries, namely Wanbang Tiancheng, Wanbang Tiansheng, Fuchuang Pharma, Wenhou Geriatrics Hospital, Zhongsheng Zhongjie and Chindex Tianjin, were included in the major subsidiaries disclosed. 3. The calculation method of total number of employees in EHS section is different from the calculation method of total number of employees in Employees section in this report, the statistical scope of number of employees for EHS section is the number of employees in service.

Data description: the statistics of the data disclosed in the above sections and each table in the EHS report are conducted in accordance with related national or local regulations, industrial standards, administrative requirements or practices formulated by subsidiaries. They are derived after reasonable verification. For the data whose validity or completeness cannot be confirmed due to various objective reasons, they are denoted with "X". For the appropriate data, they are denoted with "NA".





Yearly

In 2016, 65.6% of the total sales were generated from the domestic market.

Foreign
Product
Group




Percentage

In 2016, 23.92% of the total sales were generated from the foreign market.

Foreign
Product
Group



Value of R&D



Total R&D investment in 2016 was RMB2,194 million, an increase of 14.2% compared to 2015.

14.2%

2015.



Development

Employee

50.96% 49.04%

Category	2016	2015	Change
Domestic	50.96%	49.04%	0.36%
Foreign	2.49%	100%	-97.51%
Total	100%	100%	0%

Total cash payment for employee benefits

Cash payment for employee benefits (RMB100,000,000)

In 2016, the Group's cash payment to employees and on behalf of employees totaled RMB2,196 million,

S. S. a b e D e e e f T a e

T
P

' . A

f

f F

G

'8446 (aleO)]28nheur()11nt ou21nrani3F115 (t)11ntisiti 4.el odo6id3F115 (20F115 (16F115 (,))115 (31F115 (.0F115 (%)11n)54.F115 (th)11n)5e)11nP

S	f H	R	f F	P	G	(P)
					T	G
					M	F
2016			19,523		9,574	9,949
2015			17,842		8,653	9,189
2014			18,081		8,800	9,281
2013			16,791		8,246	8,545
2012			14,357		7,222	7,135

E	B	f E	f F	P	G	(Pe e)	
			D	M	B	D	
						S	
2016			134	1021	5,395	4,977	7,996
2015			105	889	4,453	4,643	7,752
2014			93	749	4,229	4,693	8,317
2013			80	637	3,794	4,368	7,912
2012			50	472	2,931	3,364	7,540

R	f	f F	P	G	:(f)	(P)
		R			N	f	2015	N
							f	2016
E	f C (S ,J ,A , , ,F ,S)					7,803		8,869
S	f C (G ,G ,H)					3,144		3,276
C	f C (H ,H ,H ,J)					3,110		3,442
N	f C (B ,T ,H ,S ,I M)					176		191
N	f C (N , , ,Q ,S ,G)					-		-
S	f C (S , , ,G ,T ,C)					2,038		2,001
N	f C (L ,J ,H)					1,256		1,387
H	K ,M T							14
O						315		343 j

Ta e Ed. ca

F P


T G

I 2016, C


F P

f


M , F P
G 0504 /G ,F 04 / 10.(f MT (.l 2016,
)4.2 (f)10.()4.()



Learn the German Noun System



Case: Establishment of the Wuhan University Business School




T	S	f	B
C	N		C
D	T	T	R
N	H	S	
N	M	C	I
M	T24, N	HQC	
S	C	F	P
P	T	GMP, GMP	
Q	O	P	L
EHS	N	E	O

Executive Summary

Performance Highlights

Throughout the year, we have focused on our core business and achieved significant milestones. Our financial performance has been strong, with revenue growth of 15% and a 10% increase in EBITDA. We have also made significant progress in our R&D efforts, launching three new products and securing several patents. Our customer satisfaction has improved, with a net promoter score of 45. We have also made significant progress in our sustainability efforts, reducing our carbon footprint by 10% and increasing our diversity and inclusion initiatives.



S F P (P)

S f F P 2012 2013 2014 2015 2016

T f -

160 74.37 (2014) 10.986 0 (2015) 107.308.353 405.209 0 0 74.150 0 SQ 17 4060.245 -2.338 T 4957 T -) -18 (5257 T -) -18 (6 -) -0.493 47) 8.1 (2(2013





The Me ... online



G P , f F P , CME
 .O f f f
 f f f .T f
 T ff f G P f
 f- f f f
 D.C f ,D H M





P. b. e fa. e c. b.

C. s. e. e.


>300 es
V. e e e a
a c e s

>90 es
P. b. e fa. e a
a s a d e a
c s. a

F. e g a d. e c.

1 P. e c.

H. s.



Share Value

In 2016, the company's share value increased by RMB2.99* per share. This is primarily due to the company's strong performance in the first half of the year, driven by the successful launch of its new products and the expansion of its market share. The company's share price has been steadily rising since the beginning of the year, reflecting the market's confidence in its growth prospects.

*N : S = () /



In 2016, the company's share value increased by RMB2.99* per share.

RMB2.99

8.3%

RMB 2.76 f 2015

Corporate Governance

Advanced Management

The company has established a robust corporate governance framework, including a Board of Directors, a Supervisory Board, and a Management Team. The Board of Directors is responsible for the overall strategic direction and supervision of the company's operations. The Supervisory Board monitors the company's financial and operational performance. The Management Team is responsible for the day-to-day operations and implementation of the company's strategy.

The company has also established a system of internal controls and risk management to ensure the integrity of its financial reporting and the reliability of its operations. The company's corporate governance practices are in line with the highest standards of transparency and accountability.

f F P

f

T f
I 2016, F A S D f C f -
.T f
C
I f OA D F P C F A S
D f
D f .A f 42

Ad S. De a e

T f f f F A 2016, f f
f C B f D f f F f
A S C D f C
f- f
f C f C
I 2016, f f F A S
D f f .T f
F P A -C O .T H P B f D f
E f f C P .T H P M R f
S f F F A A S S D D .I
f f
F A S D f f
A ff f 23 f
T F A S D
ff f
M F A S D f f f S D
f I 2016, F A S D
f ISO19600 C M S G

C C a

F P
RMB7.97 (I 2016, F P G).
Increased de. c c a c e
efec g e FUTURE STAR c c a s e

F P G f f F P G
f f
P G f f f F T RE STAR 1998.F
.I f f

F S. F. da

I 2016, F P RMB5.00 F F A S B C.C.T
Lf S D f F D T A .T f
f ff f .F F .T f
f f


Targeted P. e. A e

F P G f C



I 2016, F P
F F

RMB5



G , f f f

C , F P G

I 2016, F P ff f G ,

RMB6.45

F P , , H P , RMB1,000,000 C

A A (f f f f ff f D T)

F P f Lf S F C P C

f f f ff f .l 2016, :4f).

ff f RMB150,000 ;C P 29 :15 (F

J C H F P f ff f 100 - , 60 ff f

f RMB5,000,000.

T P ff f C f H f f f

9 f -

B f RMB30,000 f f f J , A P 30

f D , L T , C - - ff

.M f , RMB50,000 C J C F f 207

.17 O 2016 P f P A D ff

A f J f G 2016, G P RMB60,000 .T

H F F A P C f C C C F D

G , C C D G G , C H E C C I R

I f f f

f RMB150,000 Q D .l 2016, C R I f f

f Q D , f



L f P , I f F

M C f F

P f f

C M

Case: Joined force with Shanghai Charity Foundation to provide support to patients suffered from cancer

On 9 September, the charity day, Shanghai Charity Foundation, Fosun Foundation and Shanghai Symphony Orchestra jointly organized the charity concert of Fosun Charity Night: Let Love Fill the New World. All the donations in the event were collected through various mobile and internet charity platforms such as Tencent, Alipay, official WeChat account of Fosun Foundation (fosunfoundation) and the official website of Shanghai Symphony Orchestra, and were donated to Shanghai Charitable Cancer Research Center to finance the doctors and scientific researchers in Shanghai who devote in cancer clinical research, so as to work out the best treatment solutions for patients suffered from cancer as soon as possible.

Case: Double Thousand Actions provided timely support and care to all patients suffered from tuberculosis

On 22 March, at the promotion event of World Tuberculosis Day, Chinese Antituberculosis Association established the Chinese Anti-tuberculosis Non-profit Foundation and jointly launched the Chinese Anti-tuberculosis Non-profit Foundation - Double Thousand Actions assistance project for tuberculosis with Fosun Foundation and Hongqi Pharma (a subsidiary of Fosun Pharma). The Double Thousand Actions project will last for five years from 2016 to 2020. At least 1000 needy patients suffering from tuberculosis can be helped each year and the funding for each patient would not be less than RMB1,000. Fosun Foundation collaborates with Hongqi Pharma, a subsidiary of Fosun Pharma, to provide continuous sponsorship in the form of funding and medicine etc.

On 27 April, the 2016 National Academic Meeting of Chinese Antituberculosis Association was held in Zhuhai, Guangdong Province, and the unveiling ceremony of Chinese Anti-tuberculosis Non-profit Foundation took place at the opening ceremony.

Case: Organization of the 2nd Climb for Charity Competition by Fosun Pharma with the donation allocated to Qixiang Institute of Child Development

In February, the Climb for Charity Competition co-organized by Fosun Foundation and Fosun Pharma was held in the headquarter building of Fosun Pharma. About 22 teams participated the activity with participants covering staff of Fosun Pharma and their families, media as well as other stakeholders. All teams completed the competition within required time. The competition finally raised a total donation amount of RMB66,000.

A meeting to allocate the donation from the Climbing for Charity Competition was held in April. Six project leaders of the public welfare projects which applied for the donation presented their projects. After the voting, the Family of Children with Special Needs Rehabilitation Support Program by Shanghai Qixiang Institute of Child Development was granted the donation.

Case: Walking for Love the Shanghai United Walkathon Volunteer Event was held again

In April 2016, the Shanghai United Walkathon Volunteer Event was held again. Participants and volunteers of Fosun Pharma participated the event with full enthusiasm despite of the bad weather. With the support, accompany and encouragement of teammates and the Company's volunteers, the whole 12-hour walkathon covering a total of 50 kilometers was completed successfully with full love. Fosun Pharma volunteers have participated in the Shanghai United Walkathon charity event for four successive years and raised over RMB300,000 for supporting the children nutrition in poor areas, rural children's reading, children with autism, quality training for migrant children as well as other sectors.

Case: the Bang Program Trying the best to participate in public welfare activities

As the extension of the Company's core value of self-improvement, teamwork, performance and contribution to society as well as the inheritance of the public welfare mission of trying the best to participate in public welfare activities, the Bang Program public welfare project team expanded the activity scope in 2016 to further cover more students in poverty and fundamental hospitals in remote areas. Through preliminary study and careful selection, in 2016, the Bang Program public welfare project team of Wanbang Biopharma visited Yuanyang County and Zhengzhou in Henan Province, Jingxing County in Hebei Province and Suining County in Jiangsu Province, carried out in-depth interaction with the grassroots, supported the local education and healthcare, and further improved the local educational and medical conditions and levels, which was well recognized and encouraged by the supported students in poverty areas, fundamental medical works and experts participated in the activities.



V . Tee Tea

T 2010, f F P 100 .S
 f F P ,
 f F P ' ' f
 f f f
 S H f f f S C
 f l .
 F P S C ' f l .S 2010,
 f f f .E , ff f .I J ,
 F P T f f f
 f Q T ,M D , S C ' f l ,
 F F L f S C ' f l ,
 T f F P .F P M D ,
 D S S M S (f f) ,
 f f
 L f - C ,L T f 25 .T f f P
 f 30 f 17,000
 .C H ,1J f 10 L N f
 f 1,100 .G H S S A f
 3 5 f .T f G H

C . Se . ce

I 2016, f G 100 ,
 f .
 A P O H 2016. I f J C F f
 f 207 f G C P S
 J T ,H C C P S T ,H
 C ,
 B D P C
 f ,N , T .M ,f
 f ff
 T f f f
 f f f
 D , 90 f ff , f f .
 T 2016, G H f f f
 5,000 2 3 .M ,G H T E P f
 f f
 J C H M T P -A P R f
 S 65- - M T P P 65 C F S
 , , f C f .C H
 S f C f ff f .I 2016,
 f ,C H 21 f .T
 C f H f f .A ,



T 90 f

>90



G H f



O H D ,C
 H R ,D
 C G G
 f f



Performance Data

M		F	P	G		
I		2012 ()	2013 ()	2014	2015	2016
N	(RMB/)*	6.05	6.84	7.21	7.86	9.19
B	(RMB/)	0.80	0.90	0.92	1.07	1.21
B	f					

C	f	F	P	G	(RMB10,000)	
I		2012 ()	2013 ()	2014	2015	2016
R		734,078	999,641	1,202,553	1,260,865	1,462,882
I	I	186,598	214,062	192,501	234,662	212,540
O	P	203,599	281,883	239,435	329,717	339,942
P	-	9,725	10,436	34,047	10,666	19,511
L	-	1,020	1,692	1,676	3,200	2,298
Cf	f -	282	1,045	85	362	974
T		212,304	290,627	271,805	337,183	357,155
L		28,376	50,632	34,821	50,117	35,021
N		183,927	239,995	236,984	287,066	322,134
N	f	156,392	202,706	211,287	246,009	280,584
M		27,536	37,289	25,697	41,057	41,550
T		78,900	105,080	126,821	143,449	163,136
D		333	424	735	847	797

Note: We are a global pharmaceutical company. The data is derived from the consolidated financial statements of the Group. The data is presented in RMB10,000. The data is subject to audit. The data is presented in RMB10,000.

S da l dca

.....

.....

.....

.....

.....

.....

.....

.....

	2014	2015	2016
Total (/)	421,765,752	424,467,622	478,175,186
Employee (/)	51,835,011	52,209,518	58,815,548
Total (/) f ()	122,713,255	121,204,106	126,874,724
Contract () (/)	174,548,266	173,413,623	185,690,272
Employee f RMB10,000 (f)	171	157	126.93
Total (/)	8,377,364	8,716,937	8,769,376
f RMB10,000 (/RMB10,000)	8.23	7.89	5.99
Liability (RMB10,000)	3,200	3,166	3,346
Liability (RMB10,000) f ()	1,200	2,156	2,027
Other f (RMB10,000)	2,000	1,010	1,319
Total ()	136,637	871,123	563,081
Total (/)	5,677,448	6,285,061	6,785,400
Total f (/)	50,258	65,597	80,848.14
Total f ()	15,757	15,187	16,325
Loss f	N	0.424	0.116
Risk	N	0.533	0.21
Occupational	14.88%	12.58%	14.89%
Health S f (RMB10,000)	2,060	4,505	3,155
Total f f ()	N	71,474	93,431
D f ()	N	4.71	5.75
Employee f COD (/)	440	488	490
Employee f NH3-N (/)	60.94	56.00	60.55
Employee f (/)	90	411	466
Employee f (/)	318	408	485
Employee f (/)	130	110	19

Table fC a Names

F	f	S	f
J	B	G	C, L
S	C	B	C, L
H	F	P	C, L
S	P	C	L
	J	P	C, L
S	S	B	
P	C	L	S
J	H	P	C, L
C	P	C	L
S	H	P	C, L
C	C	f	P
S	S	(H)	B
G	P	C	L
S	H	P	C, L
J	A	P	C, L
D	A	B	C, L
H	D	P	C, L
C	P	R	I
S	H	B	C, L
S	S	T	P
S	E	P	C
S	G	C	L
A	J	C	H
	G	H	C, L
S	H	C	L
F	C	C	H
S	F	L	M
S	F	B	B
	B	(S)	C, L

F	f	S	f
T	C	M	T
C	(B)	I	T
C	M	L	
C	I	,I	
A	L	L	
H	M	I	C, L
S	T	f	T
S	L	B	T
S	F	M	S
I	S	,I	
S	F	H	T
L			
S	F	P	C, L
S	B	,I	
S	F	P	T
D	C	L	
A	T	I	
L	G		
A	,I		
C	F	P	R
C	R	P	C, L
C	S	I	T
C	T	I	T
S	F	H	I
S	,I		
G	E	C	
H		T	P
G	P	L	

T Df

GRI	A	f	G	R	I															
FSC	A	f	F	S	C															
EHS	A	f	E			,H	Sf	,												f
CAPA	A	f	C	A	&P	A														
FDA	A	f	F	D	A	(S)														
HO-PQ	f	H	O			PQ Q	f	,	P	f	,	f		PQ. I						
TO	A	f	T	O																
GMP	A	f	G	M	f	P	,													f
GMP	A	f	C	G	M	f	P	,												f
OOS	A	f	O	S	S															
SOP	A	f	S	O	P															
GCP	A	f	G	C	P															
CSR	A	f	C	-S	-R															
A	A	f																		
CME	f	T	O	M	T	P			G	P	2014									f
IT	A	f	I	f	T															f f
NGO	A	f	N	-G	O															
CE	A	f	E	C	f															f
T	T	f	f						G	E	f									T G
ISO13485	f	T	Q	M	S	f	M	D												f I O
I	f	S		(ISO)	f															f .T

S



G. Ma ce c a s s f g s d a e s s a s s e f a ce (GB 36002)

S N	C	P
Dec 88 Ma 8 g P c e s s a d S . c \ e (Z-1)		
-1-1	T f ,	15-17
-1-2	P f f f f f	3
-1-3	M f	17
-1-4	E - f	23-25, 34-39
-1-5	M ,	23-25
-1-6	M f f	24-30
-1-7	M	23, 26-31
-1-8	l	27-31
-1-9	M f	24, 100, 105-111
-1-10	M f	19-20, 24
-1-11	M f f	23-25
-1-12	M f f ,	19-22
C 8 a d 8 a c a \ g \ (R-1)		
R-1-1	R f f ,	13, 41, 55, 80-81, 98, 101
R-1-2	R f f f ,	99, 104-105
R-1-3	R f f ,	N/A
R-1-4	R f f ,	38-39
R-1-5	R f f f ,	98
R-1-6	R f f f f f	98-99
Ec 8 , s d a a d c . \ a \ g \ (R-2)		
R-2-1	D f f ,	52-53, 104-105
R-2-2	T f ,	38, 104
B a \ t \ 8 c 8 e s a d \ g \ a \ \ (R-3)		
S N	C	
R-3-1	R f f f f	99, 104-105
R-3-2	M f	92-100
R-3-3	M	98-99
R-3-4	M -	98-99

G. Da ce cass f g da + es s s e f + a ce (GB 36002)

S	C	P
N		
E e a d a e a s (L-1)		
L-1-1	N	98-99
L-1-2	N f	92-99
L-1-3	P f	92-99
L-1-4	E , f	98-99
L-1-5	N	98-99
L-1-6	N	98-99
L-1-7	P f f f	22, 98-99
L-1-8	T f ,	98-99
L-1-9	M f ,	50-51

W . g c d s a d s da + ec (L-2)

L-2-1	T f	58-60, 80-84
L-2-2	P f	80-84, 100
L-2-3	R f f	98
L-2-4	M f f	98-100
L-2-5	D f	38-39
L-2-6	E f	38-39, 98-99
L-2-7	N f	98-99
L-2-8	P f	92-100
L-2-9	R f f ,	92-100
L-2-10	R f f f	98-100
L-2-11	C f f	98-99

De ca g e a cea dc ec ed c s s (L-3)

S	C	
N		
L-3-1	M f	99
L-3-2	E f	99, 104-105
L-3-3	M	98-99, 104-105
L-3-4	E f	98-99, 104-105
L-3-5	T f	21-22, 104-105

Occ a a ea a d safe (L-4)

G. Data ce cass f g s da + es s s s e f + a ce (GB 36002)

S N	C	P
L-4-1	T , f f	58
L-4-2	C f f	80-81
L-4-3	T f f	80
L-4-4	C f	81
L-4-5	P f f f f f	83-84
L-4-6	R f f	81-82
L-4-7	S f f	81
L-4-8	E f f	81
L-4-9	M f	81
L-4-10	P f f f	86-88
L-4-11	P f f	89

De e e a d a g s f + e s (L-5)

L-5-1	P f f	93-97
L-5-2	M	98-99
L-5-3	P f f	98-99

P. e e f . s (H-1)

H-1-1	T f f	58-59
H-1-2	T f f f	71-74
H-1-3	M , f	71-74
H-1-4	M , f	71-74
H-1-5	T f	71-74
H-1-6	M	71-74
H-1-7	P f f f	75-76
H-1-8	S f f	75-76
H-1-9	P f f	60

T e. e f s a b e e s . e s (H-2)

H-2-1	T f f ,	60-63
H-2-2	M , ,	60-63
H-2-3	R f ,	64-65
H-2-4	M -	64

G. Da ce cass f g da e s b e f a ce (GB 36002)

S	C	P
N		
H-2-5	M	65
H-2-6	M	f f 64-65, 72-73
H-2-7	M	78
H-2-8	P	f f f 58-61
H-2-9	M	57-89

A e a dada a e c a e c a ge (H-3)

H-3-1	T	f f f	79-80
H-3-2	M		79-80
H-3-3	M	f	79-80
H-3-4	E	f f f f f	60-65
H-3-5	M	f f f (GHG)	79
H-3-6	E	f	64-65
H-3-7	M	f	79-80
H-3-8	T	f f f f	60-61
H-3-9	M		79
H-3-10	M	f f	N S

E e a e c , b d e s a d e e c e f e a a a b a (H-4)

H-4-1	T	f f	79
H-4-2	T	f	79
H-4-3	C	f	79
H-4-4	I	f	65, 79
H-4-5	M	f	79
H-4-6	T	f	61-77
H-4-7	M	f f f	N E
H-4-8	T	f f	N A
H-4-9	T	f f	78
H-4-10	E	f	79

G. Da ce cass f g da es s e f a ce (GB 36002)

S	C	P
N	M	
H-4-11	f f f	79

A c . (G-1)

G-1-1	T f f	104-105
G-1-2	T f , - ,	105
G-1-3	T , f	105
G-1-4	M - f ,	104-105
G-1-5	M f	19
G-1-6	E f -	104-105
G-1-7	T , f , f f ,	104-105
G-1-8	T f	N E
G-1-9	T - , -	104-105
G-1-10	M	104-105

Fa C e (G-2)

G-2-1	T f	48
G-2-2	P f	N S
G-2-3	M f f	48
G-2-4	M - -	N E
G-2-5	Rf f f f f	98-99

P f s da es s e . a . e c a (G-3)

G-3-1	T f ,	50
G-3-2	M	50
G-3-3	D f f f	28
G-3-4	M	N S
G-3-5	M f f	N S
G-3-6	F f f f	50

Re ec f , e . (G-4)

G-4-1	T f	34
G-4-2	8-99G-4-4	

G. Ȧa ce cass Ȧ g s da + es sȦȦȦ e f + a ce (GB 36002)

S	C	P
N	M	
-3-2	f	44-46

C s. e s e. Ȧe, s. + a dc aȦ s a ddȦ . es a dȦ g (X-4)

-4-1	M	47
-4-2	T	47
-4-3	T	f f N S
-4-4	T f	f - 48
-4-5	A	f f f - 27, 48
-4-6	R	f f f f 27, 48
-4-7	T	, 27, 47-48

C s. e l f + aȦ P Ȧ ecȦ a d PȦ ac (X-5)

-5-1	R	f 47-48
-5-2	N	f f f f 47-48
-5-3	L	f f f 47-48
-5-4	C	f f 47-48
-5-5	N	f f , f f f 47-48
-5-6	M	f f 47-48
-5-7	A	f f f f f f 22
-5-8	P	f f f f , f 22
-5-9	P	f f f f f 22

Ac . ȦȦȦ fbaȦ Ȧe . Ȧe (X-6)

-6-1	I	f f f f , 48
-6-2	P	f f f f 98
-6-3	T	f f f 47
-6-4	M	f f f - 48
-6-5	F	f f N E

G. Da ce cass f g s da e s s s s e f a ce (GB 36002)

S	C	P
N	S	
-6-6		47, 53

Ed. ca a d A a e e s s (X-7)

-7-1	C - f)	f (86-88
-7-2	C - , f ,	f	48
-7-3	C - f	f	48
-7-4	C - , , f	f f f	27
-7-5	C -	f	27
-7-6	C -	f	N S
-7-7	C -		N S
-7-8	C - ,	f	N S
-7-9	C -		27
-7-10	C -	f	N S

S da Pa a a (S-1)

S-1-1	C f		108
S-1-2	F	' f	N E
S-1-3	P		105, 107
S-1-4	M		104-105
S-1-5	I	f	108
S-1-6	M f	' ,	108

Ed. ca a d C e (S-2)

S-2-1	F	f f	106
S-2-2	M	f	106
S-2-3	A	f	107
S-2-4	P	f	
S-2-5	A		

E e e a d s s de e e (S-3)

S-3-1	E		92
S-3-2	T	f	93-94
S-3-3	M		50
S-3-4	M	f	92

GRI 303: Water

N	C	P	f	-	f	P
G4 GENERAL STANDARD DISCLOSURES						
STRATEGIC AND ANALYTICAL						
G4-1*	C	CEO, ,	f		f	3
G4-2	P	f				3, 4, 16-17, 139
ORGANIZATIONAL PROFILE						
G4-3*	R	f				F C , 11, 13, B C
G4-4*	R					12, 44
G4-5*	R	f				B C
G4-6*	R	f			f	12, 18
G4-7*	R	f		f		4, 11, 19
G4-8*	R					18, 35-37, 42, 44
G4-9*	R	f				12
G4-10*	.R		f			
NGC	.R		f			
	.R	f				
	.R	f				
	.R		f		f	92-93, 99
	f . R	f	f-		f	
G4-11*	R	f				98
OECD/ NGC	D					50, 78
G4-12*	R	f				14, 27-30, 50
G4-13*	R					46, 104-105
G4-14*	L					29-30
G4-15*	L	f				31
IDENTIFIED MATERIAL ASPECTS AND BOUNDARIES						
G4-17*	.L		f		f	4, 116-117
G4-18*	.E	f		A	B	23, 117, 139
	.E			R	P	f D R
	C					
G4-19*	.L	A	f			23

*Note: The table is based on the GRI 303: Water disclosure data available in the GRI 303: Water disclosure table of the GRI 303: Water disclosure table. The table is based on the GRI 303: Water disclosure data available in the GRI 303: Water disclosure table.

G ba Re + 3 gl 3a 3 e G4 l d a + I de

N	C	P
G4-20*	F A , A B	23
G4-21*	F A , A B	23
G4-22*	R ff f f f f	112-113
G4-23*	R f S A B	4, 12, 117

STAKEHOLDER ENGAGEMENT

G4-24*	P f	26-30
G4-25*	R f f	26-30
G4-26*	R , f f f	26-30
G4-27*	R ,	26-30

REPORT PROFILE

G4-28*	R () f f	4
G4-29*	D f (f)	4
G4-30*	R (,)	4
G4-31*	P f	115
G4-32*	.R , ' , .R GRI C l f (,) .R f E A R , f .GRI f	4, 131-138
G4-33*	.R , f .f , f .R .R f ,	4, 121, 140-141

GOVERNANCE

G4-34*	R .l f f , f - f ,	19-20
G4-35	R f f , f	19-20
G4-36	R f , ,	19-20
G4-37	R f , .f ,	23-25
G4-38	R f	19-20
G4-39	R C f (, f ,)	19-20
G4-40	R f f	19-20

G ba Re - 3 gl 3a 3 e G4 I d 3a - I de

N	C	P
G4-EC2	F	58-59
G4-EC3	C f	39,98
G4-EC4	F f	
Ma e P e e ce		
G4-EC5	R f	39,90
G4-EC6	P f f f f	92-93
I d e c Ec - I ac		
G4-EC7	D f f	105-107
G4-EC8	S	34-35
P c e e P ac te		
G4-EC9	P f	46-48

ENVIRONMENTAL

Ma e 3		
G4-EN1	M B O	50
G4-EN2	P G M T A R I M	61-69
E e g		
G4-EN3	E C T O	65-74
G4-EN4	E C O G T O	N S
G4-EN5	E I	61
G4-EN6	R G E C	64-65
G4-EN7	R I E R G P A S	64
Wa e		
G4-EN8	T B S	61
G4-EN9	S S A B G	N S E
G4-EN10	P A T G R A R	65
B 3 d e 3		
G4-EN11	O S O , L , M I , O A T , P A A A G	N S E
G4-EN12	D G S f I G A , P , A S O B I	N S E
G4-EN13	H P O R	N S E
G4-EN14	T N f I C N R L S A N C L S H I	N S E
	A A B O , B L G E R	

N	C	P
E		
G4-EN15	D G G (G)E (S 1)	79
G4-EN16	E I G G (G)E (S 2)	79
G4-EN17	O I G G (G)E (S 3)	62,79
G4-EN18	G ()	N S
G4-EN19	R f ()	N S
G4-EN20	E f - ()	N S
G4-EN21	N , ,	71
E . e s a d Was e		
G4-EN22	T	72
G4-EN23	T f	75-76
G4-EN24	T f	N S E
G4-EN25	f B C , , , I, II, III III, f	N S E
G4-EN26	I , , , f	N S E
P . d . c s a d Se . e s		
G4-EN27	E f f f	60
G4-EN28	P f	66-70
C		
G4-EN2	/GS0 6.951 0 T E f 6 0 (,) 0.5 () () .1 () -8.9 () 39.1 (,) 7.1 () 12.1-13R) 1TJ/T1_2 M	

Governance & Global Impact

N	C	P
LABOR PRACTICES AND DECENT WORK		
E		
G4-LA1	T	93, 99
G4-LA2	B	38-39, 98
G4-LA3	R	98
Lab / Manage e Res		
G4-LA4	M	98
Occ a a Hea a d Safe		
G4-LA5	P	83-84
G4-LA6	T	80-83
G4-LA7		83-84
G4-LA8	H	86-88
T a g a d Ed. ca		
G4-LA9	A	95
G4-LA10	P	93-97
G4-LA11	P	98
D e s a d E . a O		
G4-LA12	C	93
E . a Re . e a f W e a d Me		
G4-LA13	R	38-39, 98
S. e Assess e f Lab P ac t e s		
G4-LA14	P	N S
G4-LA15	S	N S E
Lab P ac t e s G e a ce Mec a s		
G4-LA16	N	98

HUMAN RIGHTS

I . e e		
G4-HR1	T	N A
G4-HR2	T	93-97

Governance and Ethics

N	C	P
A. Governance		
G4-SO7	T f f -	N S E
C. Ethics		
G4-SO8	M f f f f -	N S E
S. Assessment of Impact Score		
G4-SO9	P f	N S
G4-SO10	S f	50,78
G. Governance Mechanisms Score		
G4-SO11	N f	N S E

PRODUCT RESPONSIBILITY

C. Health and Safety		
G4-PR1	P f f	N S
G4-PR2	T f f f -	N S E
P. Product Safety and Labeling		
G4-PR3	T f f f -	44-46, 48
G4-PR4	T f f f -	N S E
G4-PR5	R f f	27, 31, 53
M. Packaging		
G4-PR6	S f	N S E
G4-PR7	T f f f -	N S E
C. Product Access		
G4-PR8	T f f	N S E
C. Ethics		
G4-PR9	M f f f -	N S E




I A , S f F P .D
 12- 50 f S f
 F P RMB300,000 f f f f
 I f f !H .A
 f f L H , f F P
 T f .H I
 , .H !

Assurance Statement of SGS



ASSURANCE STATEMENT

SGS-CSTC STANDARDS TECHNICAL SERVICES CO., LTD. SHANGHAI



Accuracy

FOSUNPHARMA's information in the report was accurate, capable to reveal more qualitative and quantitative information for stakeholders.

Timeliness

Assurance to know that the data and information was on a regular schedule and available in time. FOSUNPHARMA will report on a regular schedule with one year to assure the good timeliness.

Clarity

Report was presented different ways with words, charts, graphics and pictures, also describe with actual cases as well to ensure the stakeholders understanding easily. SGS recommended that same content in the report should be refined, such as length description of each project.

closing methods managing and
recommended that data of

o., Ltd. Shanghai Branch

Reliability

Through information and data collecting, recording, analyzing and disseminating in CSR report, the data and information was reliable. SGS energy saving project do not use the estimates of the data.

Signed:

For and on behalf of SGS-CSTC Standards Technical Services Co., Ltd.



Ben Tsang
Director, China and Hong Kong
Certification and Business Enhancement
28 Mar 2017

B-11/F, No.900, Yishan Road, Xuhui District, Shanghai, China
WWW.CN.SGS.COM

FOSUNPHARMA



Follow us on WeChat

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Building A, Fosun Hi-Tech Park, No.1289 Yishan Road, Xuhui District, Shanghai, P.R. China, 200233

Tel: +86 21 3398 7000

Fax: +86 21 33987020

For more information, please visit www.fosunpharma.com